



13/L-JM.  
09-13-91  
Election  
PATENT  
Our Docket: P31 8600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Wayne A. Border  
Erkki I. Ruoslahti

Serial No.: 07/416,656

Filed: October 3, 1989

For: INHIBITING TRANSFORMING  
GROWTH FACTOR B TO  
PREVENT ACCUMULATION OF  
EXTRACELLULAR MATRIX

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Group Art Unit: 182

Examiner: D. Saunders

RECEIVED

SEP 12 1991

GROUP 180

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as first class mail in an  
envelope addressed to: Commissioner of Patents and Trade-  
marks, Washington, D.C. 20231, on 8/30/91  
Date

By Theresa A. Brown  
Theresa A. Brown, Reg. No. 32,547

8/30/91  
Date of Signature

RESPONSE

Sir:

In response to the Office Action mailed on July 3,  
1991, Applicants request consideration of the following remarks.

Remarks

The application has been primarily examined for  
restriction purposes. The Examiner has restricted the claims  
into the following groups under 35 U.S.C. §121:

Group I:	Claims 2 and 7 directed to treatment methods with antibodies;
Group II:	Claims 3 and 8 directed to treatment methods with PDGF;
Group III:	Claims 4 and 9 directed to treatment methods with peptides;
Group IV:	Claims 11 and 12 directed to TGF- $\beta$ detection methods

Group V:                    Claims 16-18 directed to antibodies and  
                              cells producing antibodies

Claims 1, 5, 6, 10 and 13-15 are regarded as generic treatment  
claims.

In a telephone conference with the Examiner to clarify  
the restriction requirement, the Examiner indicated that an  
initial election of the treatment claims, Group IV or Group V  
must be made. If the treatment claims are elected, then a  
further election of species from Groups I-III must be made.

Applicants respectfully traverse the restriction  
requirement and contend the claims are sufficiently related that  
a search of all claims in one application would not pose a  
serious burden on the Examiner.

In order to be fully responsive, Applicants elect the  
treatment claims. Thus, claims 1-10 and 13-15 remain pending in  
the application. Applicants also elect the species of Group I  
directed to antibodies for further prosecution.

The Examiner is invited to call the undersigned  
attorney if there are any questions relating to the above-  
identified application.

Respectfully submitted,

8/30/91  
Date

Theresa A. Brown  
Theresa A. Brown

Registration No. 32,547

Telephone: (619) 535-9001

Facsimile: (619) 535-8949

PRETTY, SCHROEDER,  
BRUEGGEMANN & CLARK  
444 South Flower Street  
Suite 2000  
Los Angeles, California 90071